Last $1.79 USD
Change Today +0.02 / 1.13%
Volume 2.1K
CASI On Other Exchanges
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

casi pharmaceuticals inc (CASI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/14 - $2.34
52 Week Low
11/13/13 - $1.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

casi pharmaceuticals inc (CASI) Related Businessweek News

No Related Businessweek News Found

casi pharmaceuticals inc (CASI) Details

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company’s lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

15 Employees
Last Reported Date: 03/21/14
Founded in 1991

casi pharmaceuticals inc (CASI) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $285.2K
Principal Accounting Officer and Vice-Preside...
Total Annual Compensation: $175.1K
Chief Operating Officer, General Counsel and ...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

casi pharmaceuticals inc (CASI) Key Developments

CASI Pharmaceuticals, Inc. Appoints Rajesh C. Shrotriya to its Board of Directors

CASI Pharmaceuticals, Inc. announced the appointment of Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. to its Board of Directors. The appointment was made in connection with the recently announced acquisition of greater China rights to three of Spectrum's oncology drugs. Dr. Shrotriya brings well over thirty years of industry experience, an extensive understanding of the competitive landscape, and a deep insight into the medical science behind current and future drug therapies. Dr. Shrotriya is currently Chairman and Chief Executive Officer of Spectrum Pharmaceuticals, having first joined Spectrum in September 2000 as President and Chief Operating Officer and later appointed Chief Executive Officer in August 2002.

Spectrum Pharmaceuticals Grants CASI Pharmaceuticals Commercialization Rights in China for Three Cancer Drugs

Spectrum Pharmaceuticals (SPPI) has granted CASI Pharmaceuticals (CASI) exclusive rights to two commercial oncology drugs, Zevalin Injection for intravenous use and Marqibo for intravenous infusion, and a Phase 3 drug candidate, Captisol-EnabledTM Melphalan, for development and commercialization in China, including Taiwan, Hong Kong and Macau. Under the terms of the licensing agreement, SPPI will receive a 19.99% stake in CASI and a $1.5 million promissory note. CASI will be responsible for the development and commercialization of the three drugs, including the submission of import drug registration applications to regulatory authorities and conducting any confirmatory clinical studies in greater China.

CASI Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

CASI Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2014. Net loss for the second quarter of 2014 was $1.6 million, or $0.06 per share. This compares with a net loss of $1.9 million, or $0.07 per share, for the same period last year. For the first six months of 2014 the net loss was $3.1 million, or $0.11 per share, compared with a net loss of $3.0 million, or $0.12 per share, for the first six months of 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CASI:US $1.79 USD +0.02

CASI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $178.19 USD -1.51
Novartis AG SFr.90.15 CHF +1.05
Regeneron Pharmaceuticals Inc $360.52 USD +5.56
View Industry Companies

Industry Analysis


Industry Average

Valuation CASI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CASI PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at